Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Defense Mechanism Against Infection01:26

Defense Mechanism Against Infection

9.6K
Natural flora, body system defenses, and inflammation are natural barriers of the body against infectious agents regardless of previous exposure. Normal floras of the human body refer to the microbial population that colonizes the skin and mucous membranes.
In addition, many body organ systems have unique defenses against infection. The skin is an intact, multilayered surface preventing invasion by microorganisms unless impaired. Mucous membranes lining the mouth, nose, and eyelids are barriers...
9.6K
Feedback Inhibition00:46

Feedback Inhibition

57.1K
Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
57.1K
What are Viruses?00:50

What are Viruses?

128.0K
Overview
128.0K
Enzyme Inhibition01:30

Enzyme Inhibition

92.1K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
92.1K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

7.1K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

6.0K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antigen-specific tolerance therapies in type 1 diabetes: Disease-specific promises meet stage-specific challenges.

Autoimmunity reviews·2026
Same author

Development of a comprehensive real-world evidence dataset to inform diabetes policy: the diabetes data cell project.

BMC public health·2026
Same author

Exploring the psychosocial implications of general population screening for paediatric type 1 diabetes in Europe: Protocol for a mixed-methods study.

Diabetic medicine : a journal of the British Diabetic Association·2026
Same author

A global initiative to deliver precision health in diabetes.

Nature medicine·2024
Same author

Cost of care pathways before and after appropriate and inappropriate transfers to the emergency department among nursing home residents: results from the FINE study.

BMC geriatrics·2024
Same author

Upgrading of solid recovered fuel (SRF) by dechlorination and catalytic pyrolysis over nanocrystalline ZSM-5 zeolite.

Chemosphere·2023
Same journal

Global genomic surveillance of <i>Salmonella</i> in the environment: assessing virulence and antimicrobial resistance at scale.

mBio·2026
Same journal

Detoxifying and depolymerizing microorganisms reveal intertwined guild collaborations in the gut microbiome of the generalist macro-algivorous fish <i>Kyphosus cinerascens</i>.

mBio·2026
Same journal

Importance of manganese uptake in uropathogenic <i>Escherichia coli</i> CFT073 during urinary tract infection.

mBio·2026
Same journal

Erratum for Theriault et al., "Utilization of a CRISPRi-based <i>ex vivo</i> challenge model to reveal temporally dependent gene essentiality in intracellular <i>Mycobacterium tuberculosis</i>".

mBio·2026
Same journal

Loss of essential outer membrane functions causes drug hypersensitization in <i>Acinetobacter baumannii</i> overexpressing multidrug efflux pumps.

mBio·2026
Same journal

Identification and characterization of pumicyclin A, a novel circular bacteriocin from <i>Bacillus pumilus</i> with a dispensable leader peptide.

mBio·2026
See all related articles

Related Experiment Video

Updated: Jan 28, 2026

Determination of Biofilm Initiation on Virus-infected Cells by Bacteria and Fungi
12:33

Determination of Biofilm Initiation on Virus-infected Cells by Bacteria and Fungi

Published on: July 6, 2016

10.0K

Inhibiting Human Parainfluenza Virus Infection by Preactivating the Cell Entry Mechanism.

S F Bottom-Tanzer1,2, K Rybkina1,2, J N Bell1,2

  • 1Department of Pediatrics, Columbia University Medical Center, New York, New York, USA.

Mbio
|February 21, 2019
PubMed
Summary
This summary is machine-generated.

Researchers developed a potent antiviral compound, CM9, that prematurely activates the fusion protein of human parainfluenza virus type 3, preventing infection. Novel antibodies were also created to confirm the compound

Keywords:
antiviralconformational antibodyfusion activationparamyxovirusviral fusionviral glycoprotein antibody

More Related Videos

Zika Virus Infection of Cultured Human Fetal Brain Neural Stem Cells for Immunocytochemical Analysis
10:27

Zika Virus Infection of Cultured Human Fetal Brain Neural Stem Cells for Immunocytochemical Analysis

Published on: February 5, 2018

7.0K
Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

30.8K

Related Experiment Videos

Last Updated: Jan 28, 2026

Determination of Biofilm Initiation on Virus-infected Cells by Bacteria and Fungi
12:33

Determination of Biofilm Initiation on Virus-infected Cells by Bacteria and Fungi

Published on: July 6, 2016

10.0K
Zika Virus Infection of Cultured Human Fetal Brain Neural Stem Cells for Immunocytochemical Analysis
10:27

Zika Virus Infection of Cultured Human Fetal Brain Neural Stem Cells for Immunocytochemical Analysis

Published on: February 5, 2018

7.0K
Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

30.8K

Area of Science:

  • Virology
  • Structural Biology
  • Drug Discovery

Background:

  • Paramyxoviruses, like human parainfluenza virus type 3 (HPIV3), infect cells via membrane fusion mediated by the hemagglutinin-neuraminidase (HN) and fusion (F) proteins.
  • HN binds to host cell receptors, triggering conformational changes in F to enable viral entry.
  • Premature activation of the F protein is a promising antiviral strategy, rendering the virus non-infectious by inducing a postfusion state before receptor engagement.

Purpose of the Study:

  • To synthesize and characterize a more potent derivative of the antiviral compound CSC11, named CM9, targeting HPIV3.
  • To develop novel conformation-specific antibodies against the HPIV3 F protein to validate antiviral compound efficacy.
  • To explore CM9 and the new antibodies as tools for developing novel antiviral therapies against paramyxoviruses.

Main Methods:

  • Systematic chemical modifications of CSC11 to create the derivative CM9.
  • Assessing CM9's antiviral potency using plaque reduction, fusion inhibition, and binding avidity assays.
  • Producing novel anti-HPIV3 F conformation-specific antibodies and utilizing them to confirm F protein transition to the postfusion state in the presence of CM9.

Main Results:

  • The novel compound CM9 demonstrated enhanced potency in inhibiting HPIV3 infection compared to CSC11.
  • CM9 effectively caused premature activation of the HPIV3 F protein via interaction with HN, preventing viral fusion.
  • Newly developed conformation-specific antibodies confirmed the induction of the F protein's postfusion state by CM9.

Conclusions:

  • CM9 represents a potent antiviral agent that functions by prematurely triggering the HPIV3 F protein, offering a new therapeutic avenue.
  • The novel postfusion-specific antibodies are valuable tools for assessing the efficacy of antiviral compounds targeting viral fusion.
  • The combined development of CM9 and these antibodies advances the understanding of HN-F interactions and supports the creation of effective paramyxovirus antivirals.